Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Sex-Specific Impact of Metabolic Dysfunction-Associated Fatty Liver Disease on Incident Cardiovascular Diseases and Mortality Publisher Pubmed



Abbaszadeh M1 ; Hosseinpanah F2 ; Tohidi M3 ; Karimpour Reyhan S1 ; Mahdavi M2 ; Valizadeh M2
Authors

Source: Endocrinology, Diabetes and Metabolism Published:2025


Abstract

Background and Aims: Considering recent revisions in the nomenclature for fatty liver disease, alongside limited data on sex-specific differences in its cardiovascular/mortality outcomes, this study aims to investigate the prevalence and impact of metabolic-associated fatty liver disease (MAFLD) on cardiovascular disease (CVD) and mortality in men and women over a 12-year follow-up period. Methods: In this large population-based cohort study, 7101 individuals aged ≥ 30 were enrolled. The prevalence of MAFLD was investigated in both genders. After excluding individuals with a history of previous CVD, 6331 participants were followed up for CVD and mortality over 12 years. Steatosis was defined as fatty liver index (FLI) ≥ 60. Multivariate-adjusted hazard ratios (HRs) were calculated for CVD and mortality. Results: The prevalence of MAFLD was 43.2%, higher in men (46.5%) than women (40.6%). Men with MAFLD (47.7 ± 12.1) were younger than women (52.2 ± 11.1). In the 12-year follow-up of 6331 individuals, multivariable-adjusted CVD HRs for MAFLD were 1.36 (1.10–1.67) in men and 1.48 (1.16–1.88) in women. Adjusted mortality HRs were 1.17 (0.86–1.59) and 1.38 (1.00–1.91) in men and women, respectively. Among patients with MAFLD, a subgroup with diabetes faced the highest hazard for CVD and mortality. Conclusion: This study found that MAFLD is more common in men at a younger age. Despite the higher prevalence in men, women with MAFLD face a greater risk of cardiovascular events and mortality. Findings highlight the importance of gender-specific considerations in primary prevention programmes for MAFLD-related cardiovascular disease and mortality. © 2025 The Author(s). Endocrinology, Diabetes & Metabolism published by John Wiley & Sons Ltd.
Related Docs
View other Related Docs
1. Fibrosis Score 4 Index Has an Independent Relationship With Coronary Artery Diseases in Patients With Metabolic-Associated Fatty Liver Disease, Diabetology and Metabolic Syndrome (2023)
2. Contribution of Obesity and Cardiometabolic Risk Factors in Developing Cardiovascular Disease: A Population-Based Cohort Study, Scientific Reports (2022)
3. A New Approach to Test Validity and Clinical Usefulness of the 2013 Acc/Aha Guideline on Statin Therapy: A Population-Based Study, International Journal of Cardiology (2015)
Experts (# of related papers)
View all Related Experts
Amir Anushiravani (3)
Mohammad Ali Mansournia (3)
Other Related Docs
4. Weight Loss Breaks the Bond Between Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases: A Clinical and Epidemiological Perspective, Obesity Reviews (2023)
5. Prevalence and Characteristics of Metabolic Dysfunction-Associated Fatty Liver Disease Among an Iranian Adult Population With Ethnic and Genetic Diversity: Results of the Polyiran-Liver Study, Middle East Journal of Digestive Diseases (2024)
6. Nomenclature and Definition of Metabolic-Associated Fatty Liver Disease: A Consensus From the Middle East and North Africa, The Lancet Gastroenterology and Hepatology (2021)
7. Polypill Protects Mafld Patients From Cardiovascular Events and Mortality: A Prospective Trial, Hepatology International (2023)
8. Sex Specific Impact of Different Obesity Phenotypes on the Risk of Incident Hypertension: Tehran Lipid and Glucose Study, Nutrition and Metabolism (2019)
9. Socio-Behavioral Factors Associated With Overweight and Central Obesity in Tehranian Adults: A Structural Equation Model, International Journal of Behavioral Medicine (2017)
10. Mean Versus Variability of Lipid Measurements Over 6 Years and Incident Cardiovascular Events: More Than a Decade Follow-Up, Frontiers in Cardiovascular Medicine (2022)
11. Blood Pressure and Cardiovascular Morbidity Risk in Type 2 Diabetes With Hypertension Over a Decade of Follow-Up: Evidence for J-Shaped Phenomenon, Journal of Human Hypertension (2017)
12. Associations Between Dairy Products Consumption and Risk of Type 2 Diabetes: Tehran Lipid and Glucose Study, International Journal of Food Sciences and Nutrition (2015)
13. The Clinical Value of Metabolic Syndrome and Its Components With Respect to Sudden Cardiac Death Using Different Definitions: Two Decades of Follow-Up From the Tehran Lipid and Glucose Study, Cardiovascular Diabetology (2022)
14. Advancing the Global Public Health Agenda for Nafld: A Consensus Statement, Nature Reviews Gastroenterology and Hepatology (2022)
15. Association Between Oxidative Stress and Liver Fibrosis Severity in Non-Alcoholic Fatty Liver Disease: Insights From the Pro-Oxidant Antioxidant Balance Method in a Population From Tehran and Mashhad, Iran, Frontiers in Medicine (2025)
16. Direct and Indirect Effects of Central and General Adiposity on Cardiovascular Diseases: The Tehran Lipid and Glucose Study, European Journal of Preventive Cardiology (2018)
17. Evaluation of the Correlation Between Coronary Artery Disease and Nonalcoholic Fatty Liver Disease: Is There Any Correlation?, Journal of Tehran University Heart Center (2023)
18. Atherogenic Index of Plasma Is an Independent Predictor of Metabolic-Associated Fatty Liver Disease in Patients With Type 2 Diabetes, European Journal of Medical Research (2022)
19. Dietary Consumption of Advanced Glycation End Products and Risk of Metabolic Syndrome, International Journal of Food Sciences and Nutrition (2016)
20. Efficacy of Orlistat for the Treatment of Metabolic Dysfunction–Associated Steatotic Liver Disease Patients: A Systematic Review and Meta-Analysis, Hepatology Forum (2025)